LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

Home・Aandelen Lijst・Twist Bioscience Corp

Twist Bioscience Corp

Gesloten

SectorGezondheidszorg

64.83 7.62

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

60.6

Max

65.51

Belangrijke statistieken
By Trading Economics
Inkomsten	-14M -44M
Verkoop	7M 111M
EPS	-0.71
Winstmarge	-39.761
Werknemers	979
EBITDA	-16M -40M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+5.66% upside

Dividenden
By Dow Jones
Volgende Winsten	3 aug 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	327M 3.8B
Vorige openingsprijs	57.21
Vorige sluitingsprijs	64.83

Nieuwssentiment

By Acuity

38%

62%

105 / 344 Rangschikking in Healthcare

Twist Bioscience Corp Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

26 mei 2026, 16:52 UTC

Belangrijke Nieuwsgebeurtenissen

NYMEX Overview: Brent Crude Futures Up; Iran Warns of Retaliation After US Strike -- OPIS

26 mei 2026, 23:57 UTC

Winsten

Sociedad Quimica 1Q Rev $1.76B >SQM

26 mei 2026, 23:57 UTC

Winsten

Sociedad Quimica 1Q EPS $1.28 >SQM

26 mei 2026, 23:48 UTC

Marktinformatie

Nikkei May Rise on Continued AI Enthusiasm -- Market Talk

26 mei 2026, 21:54 UTC

Winsten

Webco Industries 3Q EPS $11.61 >WEBC

26 mei 2026, 21:54 UTC

Winsten

Webco Industries 3Q Sales $179.6M >WEBC

26 mei 2026, 21:48 UTC

Marktinformatie

GE Aerospace's Repair Boom Should Last for Years -- Market Talk

26 mei 2026, 21:00 UTC

Marktinformatie

ESG Roundup: Market Talk

26 mei 2026, 20:58 UTC

Acquisities, Fusies, Overnames

Uber's $11.6 Billion Bid for DoorDash Rival Is About Future Proofing It From Robots -- Barrons.com

26 mei 2026, 20:50 UTC

Marktinformatie

Tech, Media & Telecom Roundup: Market Talk

26 mei 2026, 20:50 UTC

Marktinformatie

Auto & Transport Roundup: Market Talk

26 mei 2026, 20:50 UTC

Marktinformatie

Financial Services Roundup: Market Talk

26 mei 2026, 19:22 UTC

Marktinformatie

Cryptocurrencies Add to Losses in Afternoon Trading -- Market Talk

26 mei 2026, 19:17 UTC

Marktinformatie

Oil Recovers Some Losses on U.S.-Iran Skirmishes -- Market Talk

26 mei 2026, 18:56 UTC

Marktinformatie

U.S. Natural Gas Futures Slip in Rangebound Trading -- Market Talk

26 mei 2026, 18:03 UTC

Marktinformatie

AutoCanada Faces Soft Demand, Slow Normalization -- Market Talk

26 mei 2026, 17:42 UTC

Marktinformatie

Grains Await Fresh Trading Catalyst -- Market Talk

26 mei 2026, 17:33 UTC

Marktinformatie

Salesforce, Snowflake Could Dispel Software Bear Thesis -- Market Talk

26 mei 2026, 17:21 UTC

Marktinformatie

Canada Faces a Labor Market Squeeze -- Market Talk

26 mei 2026, 16:52 UTC

Marktinformatie

Bonds to Fund Infrastructure for Data Centers Could Be Risky -- Market Talk

26 mei 2026, 16:43 UTC

Marktinformatie

Spotify's Latest Audio Play: Magazine Articles -- Market Talk

26 mei 2026, 16:24 UTC

Marktinformatie

Dollarama's LATAM Slowdown, Australia Costs Seen as Transient -- Market Talk

26 mei 2026, 16:21 UTC

Marktinformatie

Oil Extends Gains As Strikes Add Tension to U.S.-Iran Talks -- Market Talk

26 mei 2026, 16:20 UTC

Marktinformatie

Tech, Media & Telecom Roundup: Market Talk

26 mei 2026, 16:20 UTC

Marktinformatie

Energy & Utilities Roundup: Market Talk

26 mei 2026, 16:20 UTC

Marktinformatie

Financial Services Roundup: Market Talk

26 mei 2026, 16:20 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Auto & Transport Roundup: Market Talk

26 mei 2026, 16:16 UTC

Marktinformatie

Alberta Separation Threat Poses Headwind for Canada Dollar -- Market Talk

26 mei 2026, 16:01 UTC

Marktinformatie

Bitcoin Lower as Stress Builds for Holders -- Market Talk

26 mei 2026, 15:21 UTC

Marktinformatie

Hyperliquid Pushes Up to New All-Time High -- Market Talk

Peer Vergelijking

Prijswijziging

Twist Bioscience Corp Prognose

Koersdoel

By TipRanks

5.66% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 64 USD 5.66%

Hoogste 70 USD

Laagste 56 USD

Gebaseerd op 7 Wall Street-analisten die 12-maands prijsdoelen bieden voor Twist Bioscience Corp - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

7 ratings

Buy

Hold

Sell

Gebaseerd op 7 analisten die aandelenratings hebben gegeven aan Twist Bioscience Corp - Dist in de afgelopen 3 maanden.

Sentiment

By Acuity

105 / 344 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Twist Bioscience Corp

Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc. The company was incorporated in 2013 and is headquartered in South San Francisco, California.